BioArctic AB

BIOA B

SE0010323311

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 09:30:00 16/07/2026 pm IST			5-day change	1st Jan Change
301.60 ^SEK	-2.58%		-6.51%	-2.96%

14/07	Bioarctic: LEADER study shows more than 82 percent of Leqembi patients remained stable or improved	FW
14/07	Leqembi can now be administered at home from the start of treatment in the US	FW

Goldman Sachs cuts Bioarctic price target to SEK 339 (355), reiterates Neutral - BN

Published on 05/21/2026 at 09:48 am IST

Finwire - Translated by Marketscreener - See original

Add MarketScreener to your sources

BIOARCTIC AB

-2.58%

Goldman Sachs has lowered its price target for Bioarctic to SEK 339 from SEK 355, while maintaining its Neutral rating - BN

Add MarketScreener to your sources

Latest news about BioArctic AB

14/07	Bioarctic: LEADER study shows more than 82 percent of Leqembi patients remained stable or improved	FW
14/07	Leqembi can now be administered at home from the start of treatment in the US	FW
14/07	BioArctic, Eisai Win US Approval for Leqembi Iqlik as Starting Dose of Early Alzheimer's Treatment	MT
13/07	BioArctic Says Eisai Presented New Leqembi Data	RE
13/07	Leqembi in an autoinjector showed comparable efficacy and safety to the intravenous formulation	FW
12/07	BioArctic AB and Eisai Present New Clinical Data on Leqembi Subcutaneous Autoinjector Demonstrating Comparable Efficacy and Safety to Iv Formulation in Early Alzheimer's Disease	CI
10/07	Indecap Guide Q30 fell 1.1 percent in June, weighed down by a weaker small-cap market	FW
08/07	Lancelot Sweden fell 0.8% in June, BioArctic slid despite Eli Lilly deal	FW
01/07	Alzecure CEO on the multibillion-dollar deal: 'QuantumCell can get products to market quickly'	FW
30/06	Indecap Guide Q30 rose 3.8 percent in May, Sinch posts strong gains	FW
30/06	Indecap Sverige rose 3.3% in May, steady gains despite mixed earnings picture	FW
30/06	Bioarctic: New Leqembi Data to Be Presented at AAIC 2026	FW
22/06	Hemnet Slips in Stockholm, OMXS30 Index Rises 0.4%	FW
22/06	Down in Stockholm, OMXS30 index slips 0.7%	FW
22/06	Eli Lilly, BioArctic Sign Neurodegeneration Research Deal Worth Up to $800 Million	MT

BioArctic AB is a Swedenâ€‘based biopharmaceutical company specializing in the discovery and development of diseaseâ€‘modifying treatments for neurodegenerative disorders. The Companyâ€™s primary focus is on conditions that affect the central nervous system (CNS), including Alzheimerâ€™s disease, Parkinsonâ€™s disease, and amyotrophic lateral sclerosis (ALS), areas characterized by high unmet medical need and limited effective therapies. BioArctic AB conducts advanced research and development of innovative biological drugs, with a particular emphasis on monoclonal antibodies designed to target the underlying disease mechanisms rather than only alleviating symptoms. The Company combines inâ€‘house scientific expertise with strategic collaborations with global pharmaceutical partners to advance and commercialize its therapeutic candidates worldwide.

Employees

141

Sector

Biotechnology & Medical Research

Calendar

23/07 - Earnings release - Q2 2026

More about the company